South Korean Biotech 2023, page-34

Hi Jock,
Like @QuanQuest I really don't think I can add much that hasn't already been Said. But for what it's worth I will have a go at maybe looking at it from another angle. We are nearing an inflection point, by that I don't guarantee success. Just that we will soon complete 2 clinical trials, Canine P1b and MND P1/2. I think this is possibly the moment when the company can be transformed into something special. But we will need partners to progress to a P3 Canine clinical trial along with a P2/registration clinical trial for MND, not to mention P2 Human Cancer and Antiviral Clinical trials. So it's find a partner or lots of money, from what I can see [and I'm no expert so anyone please correct me if I'm wrong] we will need a minimum of 10 million to run both trials with out partners. Forget the oppies, they will only come into play if we sign up a commercial deal or find a partner. So they will be the icing on the cake.

Having said all that I think we stand a very good chance of finding a partner, particularly for MND, a disease with no standard of care. And has a good chance of being able to treat other more prevalent neurological diseases like Parkinsons, so MPL can be a double barrel weapon.

A few days ago @Densy provided a very good review of the BODs decisions up to now, which I think was spot on. I think we are now close to taking a huge step and I'm backing the BOD to get us across the line.

Cheers